Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme

Two HIV-negative gay men receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only

Published
22 February 2015
By
Liz Highleyman
Cost-Effectiveness of Immediate Hepatitis C Treatment in Early Disease Analyzed

For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in Hepatology.

Published
20 February 2015
From
HCP Live
amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

Published
19 February 2015
From
amfAR
The Drug That Is Bankrupting America

With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

Published
18 February 2015
From
Huffington Post
Study: Door-to-door campaign linked hepatitis C patients to care

Working on the streets in medically underserved Philadelphia neighborhoods, members of the Do One Thing program have been able to identify residents chronically infected with hepatitis C and help them overcome the hurdles that prevent people from being cured, according to a new study in the Journal of General Internal Medicine.

Published
16 February 2015
From
Eurekalert Inf Dis
Healthcare: The race to cure rising drug costs

The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

Published
13 February 2015
From
Financial Times
Health News Review analysis of Reuters' coverage of new hepatitis C drugs

We wish that more stories would bring some skeptical thinking to their coverage of expensive new hepatitis C treatments. The emphasis on short-term effects obscures the lack of long-term data about benefits.

Published
13 February 2015
From
Health News Review
UNITAID: 2015 Hepatitis C medicines technology and market landscape

This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

Published
13 February 2015
From
UNITAID
Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

Published
13 February 2015
From
Reuters
Gilead expects big increase in Europeans treated with hep C drug

Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.

Published
11 February 2015
From
Reuters

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.